vs
Side-by-side financial comparison of Cheche Group Inc. (CCG) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $32.8M, roughly 1.2× Cheche Group Inc.). Cheche Group Inc. runs the higher net margin — 0.5% vs -161.8%, a 162.3% gap on every dollar of revenue.
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
CCG vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.8M | $38.3M |
| Net Profit | $153.6K | $-61.9M |
| Gross Margin | 5.7% | 99.0% |
| Operating Margin | — | -169.0% |
| Net Margin | 0.5% | -161.8% |
| Revenue YoY | — | 407.0% |
| Net Profit YoY | — | -4.7% |
| EPS (diluted) | $0.00 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $32.8M | — | ||
| Q4 25 | — | $38.3M | ||
| Q3 25 | — | $32.1M | ||
| Q2 25 | $26.0M | $26.4M | ||
| Q1 25 | — | $16.5M | ||
| Q4 24 | $18.6M | $7.6M | ||
| Q3 24 | — | $6.1M | ||
| Q2 24 | $36.1M | — |
| Q1 26 | $153.6K | — | ||
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-67.3M | ||
| Q2 25 | $-492.4K | $-92.6M | ||
| Q1 25 | — | $-129.6M | ||
| Q4 24 | $-196.7K | $-59.2M | ||
| Q3 24 | — | $-85.7M | ||
| Q2 24 | $-7.6M | — |
| Q1 26 | 5.7% | — | ||
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | 4.9% | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 4.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -169.0% | ||
| Q3 25 | — | -173.5% | ||
| Q2 25 | -2.0% | -269.8% | ||
| Q1 25 | — | -390.1% | ||
| Q4 24 | -0.3% | -919.0% | ||
| Q3 24 | — | -1314.3% | ||
| Q2 24 | -4.7% | — |
| Q1 26 | 0.5% | — | ||
| Q4 25 | — | -161.8% | ||
| Q3 25 | — | -209.8% | ||
| Q2 25 | -1.9% | -350.3% | ||
| Q1 25 | — | -784.9% | ||
| Q4 24 | -1.1% | -783.4% | ||
| Q3 24 | — | -1404.0% | ||
| Q2 24 | -21.0% | — |
| Q1 26 | $0.00 | — | ||
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | $-0.01 | $-0.10 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | $-0.00 | $-0.08 | ||
| Q3 24 | — | $-0.14 | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.0M | $242.8M |
| Total DebtLower is stronger | $193.3K | — |
| Stockholders' EquityBook value | — | $-500.5M |
| Total Assets | $203.5M | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $20.0M | — | ||
| Q4 25 | — | $242.8M | ||
| Q3 25 | — | $257.8M | ||
| Q2 25 | $23.1M | $153.7M | ||
| Q1 25 | — | $61.6M | ||
| Q4 24 | $21.1M | $149.8M | ||
| Q3 24 | — | $130.4M | ||
| Q2 24 | $28.2M | — |
| Q1 26 | $193.3K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $690.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-500.5M | ||
| Q3 25 | — | $-524.3M | ||
| Q2 25 | $47.1M | $-570.7M | ||
| Q1 25 | — | $-591.4M | ||
| Q4 24 | $49.1M | $-489.1M | ||
| Q3 24 | — | $-745.1M | ||
| Q2 24 | $48.6M | — |
| Q1 26 | $203.5M | — | ||
| Q4 25 | — | $501.9M | ||
| Q3 25 | — | $519.0M | ||
| Q2 25 | $177.3M | $402.1M | ||
| Q1 25 | — | $303.8M | ||
| Q4 24 | $177.7M | $382.9M | ||
| Q3 24 | — | $364.6M | ||
| Q2 24 | $139.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-70.4M |
| Free Cash FlowOCF − Capex | — | $-71.3M |
| FCF MarginFCF / Revenue | — | -186.2% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-70.4M | ||
| Q3 25 | — | $-68.9M | ||
| Q2 25 | $-44.7M | $-79.7M | ||
| Q1 25 | — | $-85.9M | ||
| Q4 24 | $-15.8M | $-85.1M | ||
| Q3 24 | — | $-98.8M | ||
| Q2 24 | $-1.0K | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-71.3M | ||
| Q3 25 | — | $-69.6M | ||
| Q2 25 | — | $-80.8M | ||
| Q1 25 | — | $-87.0M | ||
| Q4 24 | $-16.0M | $-87.3M | ||
| Q3 24 | — | $-101.6M | ||
| Q2 24 | $-1.1K | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -186.2% | ||
| Q3 25 | — | -217.2% | ||
| Q2 25 | — | -305.9% | ||
| Q1 25 | — | -526.9% | ||
| Q4 24 | -85.9% | -1155.4% | ||
| Q3 24 | — | -1663.2% | ||
| Q2 24 | -0.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | 1.2% | 28.0% | ||
| Q3 24 | — | 45.7% | ||
| Q2 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
